Breaking News Instant updates and real-time market news.

PCRX

Pacira

$35.40

-4.45 (-11.17%)

, HRTX

Heron Therapeutics

$39.55

8.85 (28.83%)

15:42
06/21/18
06/21
15:42
06/21/18
15:42

Pacira's Exparel may face greater threat from Heron drug, says BMO Capital

BMO Capital analyst Gary Nachman said the newly released Phase 2b data for Heron Therapeutics' (HRTX) HTX-011 in post-surgical pain support a "very solid profile" for the drug, which he thinks will eventually likely be a "viable competitor" to Pacira's (PCRX) Exparel. Given the new data, a more cautious long-term outlook for Exparel may be warranted, contends Nachman, who keeps a Market Perform rating on Pacira shares. In late day trading, Heron shares are up 29% to $39.70, while Pacira has fallen 12% to $34.98.

PCRX

Pacira

$35.40

-4.45 (-11.17%)

HRTX

Heron Therapeutics

$39.55

8.85 (28.83%)

  • 21

    Jun

  • 26

    Jun

  • 27

    Jun

PCRX Pacira
$35.40

-4.45 (-11.17%)

04/23/18
CANT
04/23/18
NO CHANGE
Target $40
CANT
Overweight
Doctor call supports Cantor's positive thesis on Heron Therapeutics
After hosting a conference call with two physicians to better understand how HTX-011 will fit into the post-operative pain market, Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Heron Therapeutics (HRTX) with a $40 price target. Both physicians do not see Pacira Pharmaceuticals' (PCRX) Exparel being used anymore if HTX-011 is approved, Chen tells investors in a research note. The doctors believe that HTX-011 is a better drug that is likely to be priced lower than Exparel, the analyst points out. Chen says the call supports her positive thesis on Heron.
05/03/18
HCWC
05/03/18
NO CHANGE
Target $48
HCWC
Buy
Pacira being conservative with no guidance raise, says H.C. Wainwright
Pacira Pharmaceuticals this morning posted solid Q1 Exparel sales of $74M, just ahead of the Street's $73.1M estimate and up over 9% year-on-year, H.C. Wainwright analyst Oren Livnat tells investors in a research note. He found it important that management highlighted strong intra-quarter growth trends with 6% growth in January accelerating to 15% in March. The analyst believes, however, that investors are concerned with no Exparel guidance increase and "confusing potential near-term Exparel reimbursement developments, or lack thereof." Livnat believes management is being conservative with the outlook and reiterates a Buy rating on Pacira with a $48 price target. The stock in midday trading is down 4% to $32.95.
05/04/18
JMPS
05/04/18
NO CHANGE
Target $56
JMPS
Outperform
Pacira price target lowered to $56 from $65 at JMP Securities
JMP Securities analyst Donald Ellis noted that Pacira Pharmaceuticals reported Q1 earnings that were in-line with consensus and the company reiterated FY18 Exparel sales guidance. He lowered his price target on Pacira to $56 from $65 to account for his updated peer PEG ratios. Ellis maintains an Outperform rating on Pacira, stating that he believes the combination of the DPS partnership, scrutiny against opioids and recent approvals are contributing to the acceleration in Exparel sales.
06/06/18
JEFF
06/06/18
NO CHANGE
Target $49
JEFF
Buy
Pacira sales inflection may 'finally be underway,' says Jefferies
After hosting an investor dinner with Pacira Pharmaceuticals (PCRX) CEO Dave Stack, Jefferies analyst David Steinberg believes a "meaningful sales inflection for Exparel may finally be underway." Management is increasingly confident that an Exparel sales inflection, driven by the Johnson & Johnson (JNJ) partnership and expanded nerve block indication, is underway, Steinberg tells investors in a research note. Further, he believes a "potentially significant" Exparel rest-of-work partnership is likely to be announced prior to the end of 2018. The analyst keeps a Buy rating on Pacira Pharmaceuticals with a $49 price target.
HRTX Heron Therapeutics
$39.55

8.85 (28.83%)

06/21/18
EVER
06/21/18
NO CHANGE
Target $80
EVER
Outperform
Heron Therapeutics price target raised to $80 from $56 at Evercore ISI
Evercore ISI analyst Josh Schimmer raised his price target on Heron Therapeutics to $80 from $56 after the company announced positive topline results from two Phase 2b studies of HTX-011.
06/21/18
06/21/18
NO CHANGE
Target $80

Outperform
Heron Therapeutics price target raised to $80 on positive HTX-011 results at Evercore ISI
As previously reported, Evercore ISI analyst Josh Schimmer raised his price target for Heron Therapeutics to $80 from $56 after the company reported data from its two Phase 2b studies of HTX-011 for prevention of post-op pain following total knee arthroplasty and breast augmentation. The analyst notes that these were primarily for procuring a broad post-surgical label based on the highly compelling Phase 3 studies of the product in bunionectomy and hernia repair by demonstrating safety and predictable PK. HTX-011 not only demonstrated the required safety and PK profile to support a broad label, but the results showed clear clinical benefit over both placebo and bupivacaine, Schimmer adds. The analyst reiterates an Outperform rating on the shares.
06/21/18
CANT
06/21/18
NO CHANGE
Target $40
CANT
Overweight
Cantor has $59 per share 'bull case scenario' for Heron Therapeutics
Cantor Fitzgerald analyst Louise Chen says the positive data announced this morning by Heron Therapeutics will support the new drug application filing for HTX-011 and expand the commercial opportunity for the drug. The analyst continues to believe that the peak sales potential for HTX-011 is being underappreciated. She has a $40 price target on the shares with a $59 "bull case scenario." Chen keeps an Overweight rating on Heron Therapeutics. The stock in morning trading is up 30% to $39.82.
06/21/18
NEED
06/21/18
NO CHANGE
Target $66
NEED
Buy
Heron Therapeutics price target raised to $66 from $42 at Needham
Needham analyst Serge Belanger raised his price target on Heron Therapeutics to $66 after the company announced positive topline results from two Phase 2b studies of HTX-011 for prevention of post-op pain following total knee arthroplasty and breast augmentation.

TODAY'S FREE FLY STORIES

DTEA

DavidsTea

$1.95

0.06 (3.17%)

15:19
12/13/18
12/13
15:19
12/13/18
15:19
Options
Davids Tea options imply 19.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
12/13/18
12/13
15:17
12/13/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
12/13/18
12/13
15:16
12/13/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$66.80

0.7 (1.06%)

15:11
12/13/18
12/13
15:11
12/13/18
15:11
Hot Stocks
Starbucks says starting new rewards program in China »

Starbucks executives…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

FFIN

First Financial

$60.53

-0.8 (-1.30%)

15:08
12/13/18
12/13
15:08
12/13/18
15:08
Hot Stocks
First Financial elects John Ruzicka Chief Information Officer »

First Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

RDNT

RadNet

$12.61

0.05 (0.40%)

15:08
12/13/18
12/13
15:08
12/13/18
15:08
Hot Stocks
RadNet and MemorialCare expand joint venture »

MemorialCare and RadNet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
12/13/18
12/13
15:05
12/13/18
15:05
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

SFLY

Shutterfly

$43.18

-1.65 (-3.68%)

15:04
12/13/18
12/13
15:04
12/13/18
15:04
Recommendations
Shutterfly analyst commentary  »

Shutterfly weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIIQ

Health Insurance Innovations

$35.90

5.835 (19.41%)

15:04
12/13/18
12/13
15:04
12/13/18
15:04
Recommendations
Health Insurance Innovations analyst commentary  »

Settlement should remove…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

COST

Costco

$225.93

-1.89 (-0.83%)

15:04
12/13/18
12/13
15:04
12/13/18
15:04
Options
Costco options imply 5.4% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HIIQ

Health Insurance Innovations

$35.90

5.835 (19.41%)

15:02
12/13/18
12/13
15:02
12/13/18
15:02
Recommendations
Health Insurance Innovations analyst commentary  »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

MRVL

Marvell

$15.53

0.18 (1.17%)

15:00
12/13/18
12/13
15:00
12/13/18
15:00
Options
Size time spread in Marvell Tech following an analyst upgrade »

Size time spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jan

  • 08

    Jan

G

Genpact

$28.14

-0.27 (-0.95%)

, EXLS

ExlService

$55.76

0.13 (0.23%)

14:57
12/13/18
12/13
14:57
12/13/18
14:57
Conference/Events
William Blair IT/BPO services analysts to hold analyst/industry conference call »

India IT/BPO Services…

G

Genpact

$28.14

-0.27 (-0.95%)

EXLS

ExlService

$55.76

0.13 (0.23%)

WNS

WNS Holdings

$46.99

-0.82 (-1.72%)

GLOB

Globant

$55.66

-1.37 (-2.40%)

PRFT

Perficient

$23.49

-0.28 (-1.18%)

VRTU

Virtusa

$41.05

1.2 (3.01%)

INFY

Infosys

$9.85

0.19 (1.97%)

WIT

Wipro

$5.30

0.19 (3.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBUX

Starbucks

$66.61

0.51 (0.77%)

14:56
12/13/18
12/13
14:56
12/13/18
14:56
Hot Stocks
Breaking Hot Stocks news story on Starbucks »

Starbucks says 80% of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

AAPL

Apple

$170.45

1.36 (0.80%)

, INTC

Intel

$48.11

0.28 (0.59%)

14:55
12/13/18
12/13
14:55
12/13/18
14:55
Recommendations
Apple, Intel analyst commentary  »

Lynx questions…

AAPL

Apple

$170.45

1.36 (0.80%)

INTC

Intel

$48.11

0.28 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Jan

SBUX

Starbucks

$66.48

0.38 (0.57%)

14:50
12/13/18
12/13
14:50
12/13/18
14:50
Options
Heavy trading in Starbucks Weekly options during the company's Investor Day »

Heavy trading in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

ADBE

Adobe

$247.50

2.06 (0.84%)

14:49
12/13/18
12/13
14:49
12/13/18
14:49
Options
Adobe options imply 7.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

CMG

Chipotle

$472.11

0.91 (0.19%)

, DANOY

Danone

$0.00

(0.00%)

14:44
12/13/18
12/13
14:44
12/13/18
14:44
Hot Stocks
Chipotle announces hiring of Chief Legal Officer and Chief Development Officer »

Chipotle Mexican Grill…

CMG

Chipotle

$472.11

0.91 (0.19%)

DANOY

Danone

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 14

    Dec

  • 06

    Feb

SBUX

Starbucks

$66.51

0.41 (0.62%)

14:41
12/13/18
12/13
14:41
12/13/18
14:41
Hot Stocks
Breaking Hot Stocks news story on Starbucks »

Starbucks says goal to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 14

    Dec

GPX

GP Strategies

$13.13

0.06 (0.46%)

14:41
12/13/18
12/13
14:41
12/13/18
14:41
Conference/Events
GP Strategies management to meet with Barrington »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Dec

TSLA

Tesla

$371.33

4.57 (1.25%)

, GOOG

Alphabet

$1,057.32

-6.24 (-0.59%)

14:41
12/13/18
12/13
14:41
12/13/18
14:41
Periodicals
Tesla's Vaish resigns to start company at Google's Area120, CNBC says »

Parag Vaish, head of…

TSLA

Tesla

$371.33

4.57 (1.25%)

GOOG

Alphabet

$1,057.32

-6.24 (-0.59%)

GOOGL

Alphabet Class A

$1,068.33

-5.33 (-0.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 03

    Mar

GPX

GP Strategies

$13.13

0.06 (0.46%)

14:40
12/13/18
12/13
14:40
12/13/18
14:40
Conference/Events
GP Strategies management to meet with Barrington »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

  • 18

    Dec

HIIQ

Health Insurance Innovations

$36.84

6.775 (22.53%)

14:40
12/13/18
12/13
14:40
12/13/18
14:40
Recommendations
Health Insurance Innovations analyst commentary  »

Health Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SPY

SPDR S&P 500 ETF Trust

$264.50

-1.03 (-0.39%)

, SPX

S&P 500

$0.00

(0.00%)

14:36
12/13/18
12/13
14:36
12/13/18
14:36
General news
NYPD says monitoring multiple bomb threats, not considered credible »

The official Twitter of…

SPY

SPDR S&P 500 ETF Trust

$264.50

-1.03 (-0.39%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:35
12/13/18
12/13
14:35
12/13/18
14:35
General news
Saudi PIF has been a swing buyer of stocks »

Saudi PIF has been a…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.